Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches
Anemia is common in cancer patients and impacts on quality of life and prognosis. It is typically multifactorial, often involving different pathophysiological mechanisms, making treatment a difficult task. In patients undergoing active anticancer treatments like chemotherapy, decreased red blood cel...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1380358/full |
| _version_ | 1797230484106772480 |
|---|---|
| author | Claudia Bozzini Claudia Bozzini Fabiana Busti Fabiana Busti Giacomo Marchi Giacomo Marchi Alice Vianello Alice Vianello Claudio Cerchione Giovanni Martinelli Domenico Girelli Domenico Girelli |
| author_facet | Claudia Bozzini Claudia Bozzini Fabiana Busti Fabiana Busti Giacomo Marchi Giacomo Marchi Alice Vianello Alice Vianello Claudio Cerchione Giovanni Martinelli Domenico Girelli Domenico Girelli |
| author_sort | Claudia Bozzini |
| collection | DOAJ |
| description | Anemia is common in cancer patients and impacts on quality of life and prognosis. It is typically multifactorial, often involving different pathophysiological mechanisms, making treatment a difficult task. In patients undergoing active anticancer treatments like chemotherapy, decreased red blood cell (RBC) production due to myelosuppression generally predominates, but absolute or functional iron deficiency frequently coexists. Current treatments for chemotherapy-related anemia include blood transfusions, erythropoiesis-stimulating agents, and iron supplementation. Each option has limitations, and there is an urgent need for novel approaches. After decades of relative immobilism, several promising anti-anemic drugs are now entering the clinical scenario. Emerging novel classes of anti-anemic drugs recently introduced or in development for other types of anemia include activin receptor ligand traps, hypoxia-inducible factor-prolyl hydroxylase inhibitors, and hepcidin antagonists. Here, we discuss their possible role in the treatment of anemia observed in patients receiving anticancer therapies. |
| first_indexed | 2024-04-24T15:29:13Z |
| format | Article |
| id | doaj.art-c927b11e5f2648af9d7e98c881b53cf5 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T15:29:13Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c927b11e5f2648af9d7e98c881b53cf52024-04-02T05:01:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-04-011410.3389/fonc.2024.13803581380358Anemia in patients receiving anticancer treatments: focus on novel therapeutic approachesClaudia Bozzini0Claudia Bozzini1Fabiana Busti2Fabiana Busti3Giacomo Marchi4Giacomo Marchi5Alice Vianello6Alice Vianello7Claudio Cerchione8Giovanni Martinelli9Domenico Girelli10Domenico Girelli11Department of Medicine, Section of Internal Medicine, University of Verona, Verona, ItalyEuroBloodNet Referral Center, Azienda Ospedaliera Universitaria Integrata Verona, Verona, ItalyDepartment of Medicine, Section of Internal Medicine, University of Verona, Verona, ItalyEuroBloodNet Referral Center, Azienda Ospedaliera Universitaria Integrata Verona, Verona, ItalyDepartment of Medicine, Section of Internal Medicine, University of Verona, Verona, ItalyEuroBloodNet Referral Center, Azienda Ospedaliera Universitaria Integrata Verona, Verona, ItalyDepartment of Medicine, Section of Internal Medicine, University of Verona, Verona, ItalyEuroBloodNet Referral Center, Azienda Ospedaliera Universitaria Integrata Verona, Verona, ItalyIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyDepartment of Medicine, Section of Internal Medicine, University of Verona, Verona, ItalyEuroBloodNet Referral Center, Azienda Ospedaliera Universitaria Integrata Verona, Verona, ItalyAnemia is common in cancer patients and impacts on quality of life and prognosis. It is typically multifactorial, often involving different pathophysiological mechanisms, making treatment a difficult task. In patients undergoing active anticancer treatments like chemotherapy, decreased red blood cell (RBC) production due to myelosuppression generally predominates, but absolute or functional iron deficiency frequently coexists. Current treatments for chemotherapy-related anemia include blood transfusions, erythropoiesis-stimulating agents, and iron supplementation. Each option has limitations, and there is an urgent need for novel approaches. After decades of relative immobilism, several promising anti-anemic drugs are now entering the clinical scenario. Emerging novel classes of anti-anemic drugs recently introduced or in development for other types of anemia include activin receptor ligand traps, hypoxia-inducible factor-prolyl hydroxylase inhibitors, and hepcidin antagonists. Here, we discuss their possible role in the treatment of anemia observed in patients receiving anticancer therapies.https://www.frontiersin.org/articles/10.3389/fonc.2024.1380358/fullanemiaactivin receptor ligand trapscancerchemotherapyhepcidiniron |
| spellingShingle | Claudia Bozzini Claudia Bozzini Fabiana Busti Fabiana Busti Giacomo Marchi Giacomo Marchi Alice Vianello Alice Vianello Claudio Cerchione Giovanni Martinelli Domenico Girelli Domenico Girelli Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches Frontiers in Oncology anemia activin receptor ligand traps cancer chemotherapy hepcidin iron |
| title | Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches |
| title_full | Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches |
| title_fullStr | Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches |
| title_full_unstemmed | Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches |
| title_short | Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches |
| title_sort | anemia in patients receiving anticancer treatments focus on novel therapeutic approaches |
| topic | anemia activin receptor ligand traps cancer chemotherapy hepcidin iron |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1380358/full |
| work_keys_str_mv | AT claudiabozzini anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT claudiabozzini anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT fabianabusti anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT fabianabusti anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT giacomomarchi anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT giacomomarchi anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT alicevianello anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT alicevianello anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT claudiocerchione anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT giovannimartinelli anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT domenicogirelli anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches AT domenicogirelli anemiainpatientsreceivinganticancertreatmentsfocusonnoveltherapeuticapproaches |